Large molecule APIs, or biologics, represent a rapidly expanding class of therapeutics built from complex biological macromolecules rather than traditional small‑molecule chemistry. These include monoclonal antibodies, recombinant proteins, peptides, nucleic acid therapeutics, and engineered cell or gene therapies. Their size, structural complexity, and biological origin fundamentally shape how they are discovered, produced, and characterized. Biologics are typically:
High molecular weight molecules (thousands to millions of Daltons)
Produced in living systems (bacteria, yeast, CHO cells)
Structurally complex, with 3D folding, glycosylation, and post translational modifications
Highly specific, often binding a single target with exceptional affinity
2. Therapeutic Roles in Drug Discovery
Block or activate signaling pathways (e.g., anti TNF antibodies)
Replace missing or defective proteins (e.g., enzyme replacement therapies)
Deliver genetic material (e.g., mRNA vaccines, siRNA)
Engage the immune system (e.g., checkpoint inhibitors, CAR T cells)
3. Analytical Characterization
Mass spectrometry for peptide mapping and glycan analysis
Capillary electrophoresis for charge variants and size heterogeneity
Bioassays to confirm potency and mechanism of action
Spectroscopy and chromatography for structural and functional assessment
Why Biologics Matter. They represent the frontier of therapeutic innovation